Proteome and Phosphoproteome Analysis in TNF Long Term-Exposed Primary Human Monocytes.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
12 Mar 2019
Historique:
received: 11 02 2019
revised: 27 02 2019
accepted: 06 03 2019
entrez: 16 3 2019
pubmed: 16 3 2019
medline: 27 6 2019
Statut: epublish

Résumé

To better understand the inflammation-associated mechanisms modulating and terminating tumor necrosis factor (TNF-)induced signal transduction and the development of TNF tolerance, we analyzed both the proteome and the phosphoproteome in TNF long term-incubated (i.e., 48 h) primary human monocytes using liquid chromatography-mass spectrometry. Our analyses revealed the presence of a defined set of proteins characterized by reproducible changes in expression and phosphorylation patterns in long term TNF-treated samples. In total, 148 proteins and 569 phosphopeptides were significantly regulated (103 proteins increased, 45 proteins decreased; 377 peptides with increased and 192 peptides with decreased phosphorylation). A variety of these proteins are associated with the non-canonical nuclear factor κB (NF-κB) pathway (nuclear factor κB (NFKB) 2, v-rel reticuloendotheliosis viral oncogene homolog (REL) B, indolamin-2,3-dioxygenase (IDO), kynureninase (KYNU)) or involved in the negative regulation of the canonical NF-κB system. Within the phosphopeptides, binding motifs for specific kinases were identified. Glycogen synthase kinase (GSK) 3 proved to be a promising candidate, since it targets NF-κB inhibiting factors, such as CCAAT/enhancer binding protein (C/EBP) β. Our experiments demonstrate that both proteome and phosphoproteome analysis can be effectively applied to study protein/phosphorylation patterns of primary monocytes. These results provide new regulatory candidates and evidence for a complex network of specific but synergistically acting/cooperating mechanisms enabling the affected cells to resist sustained TNF exposure and resulting in the resolution of inflammation.

Identifiants

pubmed: 30871024
pii: ijms20051241
doi: 10.3390/ijms20051241
pmc: PMC6429050
pii:
doi:

Substances chimiques

CCAAT-Enhancer-Binding Protein-beta 0
NF-kappa B 0
Proteome 0
Tumor Necrosis Factor-alpha 0
Glycogen Synthase Kinase 3 EC 2.7.11.26

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : SFB566/B17
Organisme : Stiftung für Pathobiochemie und Molekulare Diagnostik
ID : 2012/14
Organisme : Stiftung für Pathobiochemie und Molekulare Diagnostik
ID : 2017/19
Organisme : Stiftung für Pathobiochemie und Molekulare Diagnostik
ID : 2018/19

Références

J Biol Chem. 2001 Jun 1;276(22):19664-71
pubmed: 11278638
J Leukoc Biol. 2001 Nov;70(5):821-9
pubmed: 11698503
Biochem J. 2004 Jan 1;377(Pt 1):249-55
pubmed: 14570592
Mol Cell Biol. 2004 Oct;24(19):8671-80
pubmed: 15367685
Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9766-71
pubmed: 15985551
Clin Exp Immunol. 2005 Dec;142(3):481-9
pubmed: 16297160
J Immunol. 2006 Jul 1;177(1):665-72
pubmed: 16785565
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18619-24
pubmed: 18003900
Nat Rev Immunol. 2008 Nov;8(11):837-48
pubmed: 18927578
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Sci Signal. 2009 Feb 24;2(59):ra8
pubmed: 19244213
Cancer Res. 2009 Jun 15;69(12):4983-91
pubmed: 19491262
Cell Signal. 2009 Dec;21(12):1918-24
pubmed: 19733238
Trends Immunol. 2009 Oct;30(10):475-87
pubmed: 19781994
Br J Haematol. 2010 Mar;148(5):777-90
pubmed: 19958352
Cell. 2010 Mar 19;140(6):871-82
pubmed: 20303877
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Nat Immunol. 2011 May 22;12(7):607-15
pubmed: 21602809
Int J Alzheimers Dis. 2011;2011:505607
pubmed: 21629754
Nat Immunol. 2011 Jul 31;12(9):870-8
pubmed: 21804557
Curr Opin Immunol. 2011 Oct;23(5):613-9
pubmed: 21852080
Cell Signal. 2012 Jun;24(6):1287-96
pubmed: 22374303
Curr Pharm Des. 2012;18(13):1730-50
pubmed: 22397328
Aging Cell. 2012 Aug;11(4):617-27
pubmed: 22510478
BMC Bioinformatics. 2012;13 Suppl 16:S12
pubmed: 23176165
Nat Rev Immunol. 2013 Jan;13(1):59-66
pubmed: 23197111
Nat Rev Drug Discov. 2013 Jan;12(1):64-82
pubmed: 23237916
Carcinogenesis. 2013 Sep;34(9):1943-54
pubmed: 23671130
PLoS One. 2013 Sep 02;8(9):e73153
pubmed: 24023826
J Immunol. 2014 Apr 1;192(7):3143-55
pubmed: 24574500
Front Biosci (Landmark Ed). 2015 Jun 01;20:1116-43
pubmed: 25961549
Nat Commun. 2015 Sep 16;6:8272
pubmed: 26374165
Vaccines (Basel). 2015 Sep 10;3(3):703-29
pubmed: 26378585
PLoS One. 2015 Dec 08;10(12):e0144338
pubmed: 26646662
J Amino Acids. 2015;2015:973548
pubmed: 26881062
Nat Rev Drug Discov. 2016 Aug;15(8):551-67
pubmed: 27020098
Front Immunol. 2016 Apr 26;7:160
pubmed: 27199985
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Proteomics Clin Appl. 2017 Mar;11(3-4):
pubmed: 27860399
Cell Death Differ. 2017 Jul;24(7):1172-1183
pubmed: 28362430
Nat Rev Immunol. 2017 Sep;17(9):545-558
pubmed: 28580957
Cell Signal. 2017 Sep;37:123-135
pubmed: 28629782
Expert Rev Proteomics. 2017 Sep;14(9):825-839
pubmed: 28780899
J Immunol Res. 2017;2017:9570129
pubmed: 29250561
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212

Auteurs

Bastian Welz (B)

Institute of Clinical Chemistry, Hannover Medical School, 30625 Hannover, Germany. welz.bastian@mh-hannover.de.

Rolf Bikker (R)

Institute of Clinical Chemistry, Hannover Medical School, 30625 Hannover, Germany. bikker.rolf@mh-hannover.de.

Johannes Junemann (J)

Institute of Toxicology, Hannover Medical School, 30625 Hannover, Germany. johannes-junemann@gmx.de.
Core Unit Proteomics, Hannover Medical School, 30625 Hannover, Germany. johannes-junemann@gmx.de.

Martin Christmann (M)

Institute of Clinical Chemistry, Hannover Medical School, 30625 Hannover, Germany. christmann.martin@mh-hannover.de.

Konstantin Neumann (K)

Institute of Clinical Chemistry, Hannover Medical School, 30625 Hannover, Germany. neumann.konstantin@mh-hannover.de.

Mareike Weber (M)

Institute of Clinical Chemistry, Hannover Medical School, 30625 Hannover, Germany. weber.mareike@mh-hannover.de.

Leonie Hoffmeister (L)

Institute of Clinical Chemistry, Hannover Medical School, 30625 Hannover, Germany. leonie.hoffmeister@stud.mh-hannover.de.

Katharina Preuß (K)

Institute of Clinical Chemistry, Hannover Medical School, 30625 Hannover, Germany. preuss_katharina@gmx.de.

Andreas Pich (A)

Institute of Toxicology, Hannover Medical School, 30625 Hannover, Germany. pich.andreas@mh-hannover.de.
Core Unit Proteomics, Hannover Medical School, 30625 Hannover, Germany. pich.andreas@mh-hannover.de.

René Huber (R)

Institute of Clinical Chemistry, Hannover Medical School, 30625 Hannover, Germany. huber.rene@mh-hannover.de.

Korbinian Brand (K)

Institute of Clinical Chemistry, Hannover Medical School, 30625 Hannover, Germany. brand.korbinian@mh-hannover.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH